Blood cancers: stem cell transplant
Phase II study for testing Leflunomide to Prevent Cytomegalovirus (CMV) Reactivation in Stem Cell Transplant Patients
Who can joinAsk the trial team
AgeAsk the trial team
Kind of studyPhase 2: does it work?
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Last updated on the registry 11 Nov 2024. Please confirm with the hospital that this trial is still taking patients.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
ACTREC Tata Memorial CentreNavi MumbaiDirections ↗
Registry summary (technical)
Use of Leflunomide as Primary Prophylaxis against Cytomegalovirus (CMV) Reactivation in Haploidentical Haematopoietic Stem Cell Transplant (HIT) Single arm Phase 2 Clinical Trial - NIL
Sponsor: Tata Memorial Hospital
CTRI/2024/05/067949 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 11 Nov 2024 · read by us 5 Nov 2026